Diclofenac-induced inactivation of CYP3A4 and its stimulation by quinidine

Drug Metabolism and Disposition

Volumn 30, Issue 10, 2002, Pages 1143-1148

  Masubuchi, Yasuhiro ^a   Ose, Atsushi ^a   Horie, Toshiharu ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYDICLOFENAC; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; CYTOCHROME P450 ISOENZYME; DIAZEPAM; DICLOFENAC; DICLOFENAC DERIVATIVE; GLUTATHIONE; QUINIDINE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; TESTOSTERONE; UNCLASSIFIED DRUG; UNSPECIFIC MONOOXYGENASE;

AEROBIC METABOLISM; ARTICLE; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INACTIVATION; ENZYME MECHANISM; HETEROTROPHY; HUMAN; HUMAN TISSUE; INCUBATION TIME; LIVER MICROSOME; LYMPHOBLASTOID CELL; PRECURSOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPRODUCIBILITY;

CYTOCHROME P-450 ENZYME SYSTEM; DICLOFENAC; ENZYME ACTIVATION; ENZYME ACTIVATORS; ENZYME INHIBITORS; HUMANS; MICROSOMES, LIVER; QUINIDINE;

EID: 0036785511     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.30.10.1143     Document Type: Article

References (24)

1. Atkins WM, Wang RW, and Lu AY (2001) Allosteric behavior in cytochrome P450-dependent in vitro drug-drug interactions: a prospective based on conformational dynamics. Chem Res Toxicol 14:338-347.
2. Bort R, Mace K, Boobis A, Gomez-Lechon MJ, Pfeifer A, and Castell J (1999) Hepatic metabolism of diclofenac: role of human CYP in the minor oxidative pathways. Biochem Pharmacol 58:787-796.
3. Desai PB, Duan JZ, Zhu YW, and Kouzi S (1998) Human liver microsomal metabolism of paclitaxel and drug interactions. Eur J Drug Metab Pharmacokinet 23:417-424.
4. Fujita S, Tatsuno J, Kitani K, and Suzuki T (1990) Age-associated alterations in diazepam metabolizing enzyme activities in male and female rats. Drug Metab Dispos 18:812-814.
5. Guengefich FP, Muller-Enoch D, and Blair IA (1986) Oxidation of quinidine by human liver cytochrome P-450. Mol Pharmacol 30:287-295.
6. Halmes NC, Samokyszyn VM, Hinton TW, Hinson JA, and Pumford NR (1998) The acetaminophen regioisomer 3′-hydroxyacetanilide inhibits and covalently binds to cytochrome P450 2E1. Toxicol Lett 94:65-71.
7. Halpert JR (1995) Structural basis of selective cytochrome P450 inhibition. Annu Rev Pharmacol Toxicol 35:29-53.
8. Hosea NA, Miller GP, and Guengerich FP (2000) Elucidation of distinct ligand binding sites for cytochrome P450 3A4. Biochemistry 39:5929-5939.
9. Kent UM, Juschyshyn MI, and Hollenberg PF (2001) Mechanism-based inactivators as probes of cytochrome P450 structure and function. Curr Drug Metab 2:215-243.
10. Kenworthy KE, Bloomer JC, Clarke SE, and Houston JB (1999) CYP3A4 drug interactions: correlation of 10 in vitro probe substrates. Br J Clin Pharmacol 48:716-727.
11. Kenworthy KE, Clarke SE, Andrews J, and Houston JB (2001) Multisite kinetic models for CYP3A4: simultaneous activation and inhibition of diazepam and testosterone metabolism. Drug Metab Dispos 29:1644-1651.
12. Leemann T, Transon C, and Dayer P (1993) Cytochrome P450TB (CYP2C): a major monooxygenase catalyzing diclofenac 4′-hydroxylation in human liver. Life Sci 52:29-34.
13. Ludwig E, Schmid J, Beschke K, and Ebner T (1999) Activation of human cytochrome P-450 3A4-catalyzed meloxicam 5′-methylhydroxylation by quinidine and hydroquinidine in vitro. J Pharmacol Exp Ther 290:1-8.
14. Masubuchi Y, Ose A, and Horie T (2001) Mechanism-based inactivation of CYP2C11 by diclofenac. Drug Metab Dispos 29:1190-1195.
15. Masubuchi Y, Takahashii C, Fujio N, Horie T, Suzuki T, Imaoka S, Funae Y, and Narimatsu S (1995) Inhibition and induction of cytochrome P450 isozymes after repetitive administration of imipramine in rats. Drug Metab Dispos 23:999-1003.
16. Ngui JS, Tang W, Stearns RA, Shou M, Miller RR, Zhang Y, Lin JH, and Baillie TA (2000) Cytochrome P450 3A4-mediated interaction of diclofenac and quinidine. Drug Metab Dispos 28:1043-1050.
17. Schrag ML and Wienkers LC (2001) Covalent alteration of the CYP3A4 active site: evidence for multiple substrate binding domains. Arch Biochem Biophys 391:49-55.
18. Shen S, Marchick MR, Davis MR, Doss GA, and Pohl LR (1999) Metabolic activation of diclofenac by human cytochrome P450 3A4: role of 5-hydroxydiclofenac. Chem Res Toxicol 12:214-222.
19. Shou M, Grogan J, Mancewicz JA, Krausz KW, Gonzalez FJ, Gelboin HV, and Korzekwa KR (1994) Activation of CYP3A4: evidence for the simultaneous binding of two substrates in a cytochrome P450 active site. Biochemistry 33:6450-6455.
20. Shou M, Mei Q, Ettore MW Jr, Dai R, Baillie TA, and Rushmore TH (1999) Sigmoidal kinetic model for two co-operative substrate-binding sites in a cytochrome P450 3A4 active site: an example of the metabolism of diazepam and its derivatives. Biochem J 340:845-853.
21. Tang W, Stearns RA, Kwei GY, Iliff SA, Miller RR, Egan MA, Yu NX, Dean DC, Kumar S, Shou M, et al. (1999a) Interaction of diclofenac and quinidine in monkeys: stimulation of diclofenac metabolism. J Pharmacol Exp Ther 291:1068-1074.
22. Tang W, Stearns RA, Wang RW, Chiu SH, and Baillie TA (1999b) Roles of human hepatic cytochrome P450s 2C9 and 3A4 in the metabolic activation of diclofenac. Chem Res Toxicol 12:192-199.
23. Ueng YF, Kuwabara T, Chun YJ, and Guengerich FP (1997) Cooperativity in oxidations catalyzed by cytochrome P450 3A4. Biochemistry 36:370-381.
24. Yasumori T, Nagata K, Yang SK, Chen LS, Murayama N, Yamazoe Y, and Kato R (1993) Cytochrome P450 mediated metabolism of diazepam in human and rat: involvement of human CYP2C in N-demethylation in the substrate concentration-dependent manner. Pharmacogenetics 3:291-301.